We are live on ! Find out more
RDY icon

Dr. Reddy's Laboratories

230 hedge funds and large institutions have $1.73B invested in Dr. Reddy's Laboratories in 2024 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 92 increasing their positions, 73 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more call options, than puts

Call options by funds: $1.91M | Put options by funds: $733K

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

26% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 73

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

3% more funds holding

Funds holding: 223230 (+7)

2% more capital invested

Capital invested by funds: $1.7B → $1.73B (+$37.4M)

2.23% less ownership

Funds ownership: 73.05%70.81% (-2.2%)

Holders
230
Holders Change
+7
Holders Change %
+3.14%
% of All Funds
3.31%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
29
Increased
92
Reduced
73
Closed
20
Calls
$1.91M
Puts
$733K
Net Calls
+$1.18M
Net Calls Change
-$648K
Name Holding Trade Value Shares
Change
Change in
Stake
MIFH
76
Migdal Insurance & Financial Holdings
Israel
$1.87M +$986K +67,500 +113%
US Bancorp
77
US Bancorp
Minnesota
$1.82M -$1.47M -100,775 -45%
Nordea Investment Management
78
Nordea Investment Management
Sweden
$1.73M -$29.2K -2,000 -2%
GT
79
Greenleaf Trust
Michigan
$1.72M +$4.23K +290 +0.2%
BNP Paribas Asset Management
80
BNP Paribas Asset Management
France
$1.71M +$21.3K +1,460 +1%
VFA
81
Virtus Fund Advisers
Connecticut
$1.7M +$1.69M +115,860 New
VA
82
Vident Advisory
Georgia
$1.68M +$59.7K +4,090 +4%
S
83
SignatureFD
Georgia
$1.65M +$94K +6,440 +6%
LPL Financial
84
LPL Financial
California
$1.64M +$1.64M +112,045 New
GC
85
Guggenheim Capital
Illinois
$1.63M -$157K -10,755 -9%
BCAM
86
Boston Common Asset Management
Massachusetts
$1.57M
SCM
87
Shelton Capital Management
Colorado
$1.53M -$13.9K -955 -0.9%
Mariner
88
Mariner
Kansas
$1.47M +$154K +10,540 +12%
Fidelity Investments
89
Fidelity Investments
Massachusetts
$1.45M -$11.8K -805 -0.8%
Walleye Capital
90
Walleye Capital
New York
$1.43M -$5.11M -349,740 -78%
OAC
91
OMERS Administration Corp
Ontario, Canada
$1.37M -$854K -58,500 -38%
Cerity Partners
92
Cerity Partners
New York
$1.28M +$364K +24,950 +40%
HJIM
93
Henry James International Management
New York
$1.28M -$25.3K -1,735 -2%
Victory Capital Management
94
Victory Capital Management
Texas
$1.26M
Pathstone Holdings
95
Pathstone Holdings
New Jersey
$1.25M -$89.9K -6,155 -7%
Axa
96
Axa
France
$1.24M
II
97
Inspire Investing
Idaho
$1.17M -$756K -51,765 -39%
RWM
98
Ritholtz Wealth Management
New York
$1.16M +$148K +10,115 +15%
Amundi
99
Amundi
France
$1.13M -$5.93M -406,035 -84%
Balyasny Asset Management
100
Balyasny Asset Management
Illinois
$1.13M +$587K +40,205 +110%

RDY Hedge Fund Activity: Q1 2024 in Review

230 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q1 2024, worth a combined $1.73B — up 2.2% from $1.7B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new RDY positions and 20 closed out — a net gain of 9 holders — while 92 added to existing stakes and 73 trimmed.

The largest buyer was Bank of America, adding an estimated $24M. The largest seller was BlackRock, cutting an estimated $60.1M.

  • 230 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q1 2024, up from 223 in Q4 2023.
  • Funds reported $1.73B of Dr. Reddy's Laboratories stock for Q1 2024, up 2.2% quarter-over-quarter.
  • 29 funds opened new Dr. Reddy's Laboratories positions in Q1 2024 and 20 closed out, a net change of +9 holders.
  • The largest Dr. Reddy's Laboratories buyer in Q1 2024 was Bank of America, an estimated $24M added.
  • The largest Dr. Reddy's Laboratories seller in Q1 2024 was BlackRock, an estimated $60.1M sold.

Based on aggregated 13F filings for Q1 2024.